Abstract:BACKGROUND: Onychomycosis is one of the commonest dermatological diseases worldwide. The antifungal activity of current medications varies, and treatment failure occurs in 25-40% of treated patients.AIMS: To evaluate the in vitro antifungal activity of itraconazole, fluconazole, terbinafine and voriconazole against isolates taken from patients with onychomycosis.METHODS: Nail isolates were evaluated according to methods described in the protocols of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST) and the Clinical and Laboratory Standards Institute (CLS M38-A), and a CLSI M38-A modified technique for dermatophytes. Antifungal agents tested included terbinafine, itraconazole, voriconazole and fluconazole.RESULTS: In total, 103 isolates of Candida species (n = 58), Fusarium species (n = 10), Fusicoccum dimidiatum (n = 4), Scytalidium hyalinum (n = 1) and dermatophytes (n = 30) were evaluated. Itraconazole and voriconazole were the most active agents against Candida species, whereas terbinafine and voriconazole were most potent against dermatophytes. Fusarium species had the highest minimum inhibitory concentration (MIC) values with all antifungal agents.CONCLUSIONS: The aetiological agents of onychomycosis that we found differ from those found in other countries, suggesting that the heat and humidity of the Colombian climate could favour yeast nail infections. The lowest MICs for Candida species (obtained with voriconazole, followed by itraconazole) may be explained by emerging resistant strains. Against dermatophytes, the lowest MICs were obtained with terbinafine, followed by voriconazole. MIC values for the evaluated agents were higher for non-dermatophyte filamentous fungi than for other fungi. As MIC breakpoints have not yet been established for onychomycosis therapies, it remains unclear if in vitro activities of antifungal drugs are predictive of clinical outcome. Well-designed clinical studies are necessary to assist clinicians in choosing the best antifungal agents.

<i>In Vitro</i> Activities of Ravuconazole and Isavuconazole against Dematiaceous Fungi

In Vitro Activity of Isavuconazole and Amphotericin B in Association against Mucorales

In Vitro Interaction of Itraconazole with Amphotericin B, Caspofungin, and Terbinafine Against Clinical Isolates of Trichosporon asahii

In Vitro Interactions of Micafungin with Amphotericin B, Itraconazole or Fluconazole Against the Pathogenic Phase of Penicillium Marneffei.

In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species

In vitro activities of nine antifungal agents against rare pathogenic fungi.

In Vitro Activities of the Tetrazole VT-1161 Compared with Itraconazole and Fluconazole Against Cryptococcus and Non-Albicans Candida Species

In Vitro Activities of Nine Antifungal Drugs and Their Combinations against Phialophora verrucosa

In Vitro Activities of Nine Antifungal Drugs Against 81 Phialophora and Cyphellophora Isolates.

In Vitro Susceptibility Testing of Aspergillus Spp. Against Voriconazole, Itraconazole, Posaconazole, Amphotericin B and Caspofungin

In-vitro and In-Vivo Antifungal Activities of Posaconazole:An Update

In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis

In vitro activities of six antifungal agents and their combinations against Chaetomium spp.

In Vitro Activities of a Wide Panel of Antifungal Drugs against Various Scopulariopsis and Microascus Species

In vitro susceptibility testing of the combination of terbinafine and itraconazole against dematiaceous fungi

In vitro activities of flutrimazole against fungal pathogens isolated from tinea pedis

In vitro susceptibilities of 11 clinical isolates of Exophiala species to six antifungal drugs

In Vitro Activitiy of Rezafungin in Comparison with Anidulafungin and Caspofungin Against Invasive Fungal Isolates (2017 to 2022) in China

Comparison of In Vitro Antifungal Activities of Efinaconazole and Currently Available Antifungal Agents against a Variety of Pathogenic Fungi Associated with Onychomycosis

In Vitro Activity of Isavuconazole and Other Mould-Active Azoles against Aspergillus fumigatus with and without CYP51 Alterations

In vitro activity of posaconazole against 43 clinical isolates of zygomycetous fungi by E-test